Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9233097-B2

Patent

Publication Date

2016-01-12

Expiration Date


Abstract

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

Core Innovation

The patent addresses the poor aqueous solubility of ST-246. The disclosed invention is a liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246, hydroxypropyl-β-cyclodextrin and/or sulfobutyl ether-β-cyclodextrin, and one or more pharmaceutically acceptable ingredients. The abstract, summary, and background sections are not included in the provided partial content, so no further background context is explicitly described.

The description reports that cyclodextrins increase the aqueous solubility of ST-246, with hydroxypropyl-β-cyclodextrin performing better than sulfobutyl ether-β-cyclodextrin in the reported comparisons. Solubility is compared across cyclodextrin concentrations and types, temperature, pH, and added excipients, alongside dilution-stability data and monkey pharmacokinetic profiles. Intravenous formulations, saline compatibility upon dilution, and tolerability findings in animals are also reported.

Claims Coverage

The relevant claims include one independent claim, claim 1, directed to a liquid pharmaceutical formulation. Dependent claims 2–5 specify ingredient categories and limits on cyclodextrin content, formulation pH, and degree of substitution. The following five inventive features capture the independent claim and these dependent refinements.

Liquid pharmaceutical formulation containing ST-246 and cyclodextrin

A liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246, hydroxypropyl-β-cyclodextrin and/or sulfobutyl ether-β-cyclodextrin, and one or more pharmaceutically acceptable ingredients.

Pharmaceutically acceptable ingredient categories

The pharmaceutically acceptable ingredients are selected from carriers, excipients, diluents, additives, fillers, lubricants, and binders.

Hydroxypropyl-β-cyclodextrin content

The formulation contains hydroxypropyl-β-cyclodextrin at about 20% to about 40% by weight.

Formulation pH

The formulation has a pH between about 3 and 10.

Degree of substitution

The hydroxypropyl-β-cyclodextrin has a degree of substitution between about 4.0 and about 8.0.

The claims cover a liquid ST-246 formulation containing the specified cyclodextrins and pharmaceutically acceptable ingredients, with dependent claims defining ingredient categories and selected limits on cyclodextrin content, pH, and degree of substitution.

Stated Advantages

Cyclodextrin-based liquid formulations increase the aqueous solubility of ST-246, addressing its poor aqueous solubility.

Hydroxypropyl-β-cyclodextrin performs better than sulfobutyl ether-β-cyclodextrin in the reported solubility comparisons.

Documented Applications

A liquid pharmaceutical formulation comprising a therapeutically effective amount of ST-246, hydroxypropyl-β-cyclodextrin and/or sulfobutyl ether-β-cyclodextrin, and one or more pharmaceutically acceptable ingredients.

Intravenous formulations of ST-246, with reported compatibility with saline upon dilution.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.